FREEDOM60
Commercial- Indications
- Subcutaneous Immunoglobulin Delivery, IV Antibiotics
Company intelligence / Profile preview
KORU Medical’s Freedom Infusion System has been FDA-cleared since 1994 and supports over 2 million infusions annually. The system is widely used for home-based and ambulatory subcutaneous drug delivery, especially immunoglobulin therapies. The company also collaborates with biopharma partners in feasibility and clinical trials for new drug-device combinations. A Phase III trial collaboration in nephrology was announced in early 2025[6].
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on KORU Medical Systems.